GSK plc reported that the EMA accepted its application on January 29, 2024, to extend the use of its RSV vaccine, Arexvy, to adults aged 50-59 at increased risk for RSV disease, based on strong Phase III study results.
AI Assistant
GSK PLC
2024
6 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.